RESEARCHER PROFILE
Associate Professor Amy McCart Reed (Filmed June 2024)
Senior Principal Research Fellow,
Centre for Clinical Research
University of Queensland,
Australia
Associate Professor Amy McCart Reed holds a PhD in molecular biology from The University of Queensland. She is a Fellow of the Faculty of Science of the Royal College of Pathologists Australasia. Her early postdoctoral work focused on understanding the genetic basis of colorectal cancer using experimental disease models, as part of a Cancer Research UK-funded colorectal cancer program led by Professors Ian Tomlinson and Andrew Silver.
After returning to Australia, she was recruited to the Molecular Breast Pathology group at UQ’s Centre for Clinical Research and has undertaken a series of studies investigating the genomic landscape of breast cancer special types. Amy’s research program includes studies on Metaplastic breast cancer and Invasive Lobular Carcinoma, two breast cancer special types in need of targeted therapy options.
Assoc Prof McCart Reed is the scientific lead on an MRFF-funded (Medical Research Future Fund) genomics program investigating the potential for the application of Whole Genome Sequencing in the breast cancer care pathway in Australia, ‘Q-IMPROvE’. She applies genomics and spatial transcriptomics methodologies to archival clinical samples to understand the differences between tumour types and their potential for treatment. Amy is passionate about clinical research, biobanking and precision oncology. In addition to her breast cancer research portfolio, she is on the steering committee for the Brisbane Breast Bank and the Scientific Advisory Board for Breast Cancer Trials.
-
Visceral pain and the gut-brain axis
Professor Stuart Brierley is Director of the Visceral Pain Research Group, Director of the Hopwood Centre for Neurobiology, and Theme co-Leader of Lifelong Health at the South Australian Health and Medical Research Institute (SAHMRI).
Prof Brierley is an international expert on the ‘gut-brain axis’ and chronic visceral pain mechanisms. Current investigations are on a individual cell type called the enterochromaffin cell, and it helps signal pain and anxiety from the gastrointestinal tract to the brain.
-
World-first clinical trial improves patient outcomes for kidney transplants (2023)
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
In his father’s footsteps as a kidney transplant specialist
Since he was a young child, Dr Collins, has been interested in kidney failure and kidney transplants in particular. His father was also a kidney specialist, and he used to sit by the phone when his father, was on call and ringing people who were being offered a kidney transplant. The joy in their voices through this interaction created a lasting and profound impact on Dr Collins. This carried through his career and today he continues to seek better outcomes for Kidney patients.
